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During the course of a productive infection, human cytomegalovirus (HCMV) has a sophisticated relationship with its host
cell. An increasing number of virus-encoded genes are being identified which act specifically to usurp or modulate functions
in the host cell associated with transcriptional control, cell signalling, and protein synthesis. While HCMV infection is
associated with a general upregulation of cellular gene expression, the expression a small subset of cellular proteins,
including the MHC-1 heavy chain and fibronectin, is downregulated. This study now identifies two additional cellular proteins,
aminopeptidase N (CD13) and neutral endopeptidase (CD10), that are downregulated during HCMV infection. While amino-
peptidase N and neutral endopeptidase exhibit no significant sequence homology, both are expressed on the cell surface and
have very similar enzymatic properties. HCMV infection was associated with reduced surface expression and enzyme activity
of CD13 and CD10, an apparent decrease in the rate of synthesis of both proteins in metabolic-labelling experiments, and
inhibited glycosylation of the nascent CD13 and CD10 polypeptide chains that were synthesized. Levels of CD10 poly A1 RNA
were suppressed efficiently at all stages of virus infection; however, the reduction in CD13 poly A1 RNA levels was much less
pronounced. This differential effect suggests that HCMV may be downregulating expression of CD10 and CD13 by
independent mechanisms. Indeed, treatment of cells with an inhibitor of viral DNA synthesis blocks downregulation of CD13,
whilst downregulation of CD10 is unaffected. While it is not yet clear what advantage is bestowed on the virus by
downregulating expression of CD13 and CD10, aminopeptidases are known to have a role in peptide processing in both the
MHC class I the MHC class II antigen presentation pathways. © 1998 Academic Press
INTRODUCTION
Human cytomegalovirus (HCMV) is a widely prevalent
species-specific betaherpesvirus. Following primary in-
fection, HCMV establishes lifelong persistence, with the
virus genome detectable in myeloid progenitor cells of
healthy seropositive individuals (Mendelson et al., 1996).
Productive replication of HCMV has been observed after
in vitro maturation of monocytes, implying that such cells
may provide a mechanism for virus dissemination to
peripheral tissues in vivo (So¨derberg et al., 1997a,b).
HCMV is extremely well adapted to its host, as most
primary infections of immunocompetent individuals are
either asymptomatic or subclinical. However, reactiva-
tion of infection in immunocompromised individuals,
such as organ transplant recipients and AIDS patients, is
associated with organ-specific or disseminated disease
with high morbidity and mortality. Furthermore, HCMV
remains a major viral cause of congenital malformation
(Boppana et al., 1992).
Productive HCMV infection is most readily studied in
vitro by infection of primary human fibroblasts. In con-
trast to HSV-1, which specifically ‘‘shuts down’’ host cell
gene expression, HCMV actively stimulates host protein
synthesis. HCMV virion proteins upregulate transcription
factors NF-kB (Yurochko et al., 1995) and CREB
(Schwartz et al., 1996), while the immediate early (IE)
gene products function individually and in concert to
stimulate transcription of both cellular and HCMV genes
(Hagemeier et al., 1992; Caswell et al., 1996). Stimulation
of host cell gene expression presumably favours HCMV
DNA replication and subsequent virion production. Nev-
ertheless, the expression of some cellular proteins, in-
cluding fibronectin (Pande et al., 1990), a1/b1 integrin
(Warren et al., 1994b), and the MHC class I complex (Del
Val et al., 1992; Yamashita et al., 1993, 1994; Warren et al.,
1994a; Jones et al., 1995; Hengel et al., 1996; Lehner et
al., 1997) is downregulated after HCMV infection. HCMV-
induced downregulation of MHC-1 has been studied in
great detail to provide insight into its proposed role in
viral immune evasion and to dissect the machinery con-
trolling MHC-1-mediated antigen presentation.
At least five HCMV genes inhibit MHC-1 antigen pre-
sentation in HCMV-infected cells. The virion tegument
protein pp65 interacts specifically with the major IE pro-
tein to obscure its recognition as a CTL target (Gilbert et
al., 1996). Following HCMV infection, transcription and
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translation of the MHC-1 heavy chain is enhanced (War-
ren et al., 1994a). However, US2 and US11 gene products
induce rapid retrograde translocation of class I heavy
chains from the ER into the cytoplasm where they are
deglycosylated and degraded by proteosomes (Wiertz et
al., 1996; Machold et al., 1997). Additionally, the IE US3
gene product retains newly synthesized MHC-1 mole-
cules in the ER (Ahn et al., 1996). Finally, US6 encodes a
22-kDa glycoprotein which binds to the transporter as-
sociated with antigen processing (TAP)/MHC-I complex
preventing peptide translocation from the cytosol to the
ER, inhibiting maturation of MHC-1 (Hengel et al., 1996;
Ahn et al., 1997; Lehner et al., 1997), again favouring its
degradation.
A number of cellular proteins are also involved in the
MHC-1 antigen presentation pathway (Townsend et al.,
1990; Sadasivan et al., 1996), including one or more
aminopeptidase activities, which are postulated to be
important in trimming antigenic peptides to produce an
optimal configuration for binding in the MHC-1 groove
(Elliot et al., 1995; Koopman et al., 1996). Aminopepti-
dases catalyse the cleavage of amino acids from the
amino terminus of protein or peptide substrates. CD13
(aminopeptidase N; EC 3.4.11.2; Look et al., 1989) is
expressed both on the surface of normal and malignant
cells of myelomonocytic and granulocytic lineage (Griffin
et al., 1981; Lendeckel et al., 1994) and on many cells of
nonhaematopoetic origin, including fibroblasts (Piela-
Smith and Korn, 1995). In humans, CD13 exists as a
homodimer of an apparent molecular weight of 140–166
kDa (Hogg and Horton, 1987). CD10 (EC 3.4.24.11) is also
referred to as neutral endopeptidase, common acute
lymphoblastic leukaemia antigen (CALLA), metalloen-
dopeptidase, or enkephalinase (Devault et al., 1988; Le-
tarte et al., 1988). CD10 is a membrane-bound metallo-
protease (Semenza, 1986) that exhibits similar properties
to CD13 in terms of cellular localisation and cleavage
preference, despite their lack of significant sequence
homology (Turner et al., 1987).
The hitherto described functions of CD10 and CD13
are wide ranging, and the enzymes occasionally act
synergistically, for example, in the enzymatic inactivation
of the bioactive peptide bradykinin in the brain (Graf et
al., 1993). Peripheral blood lymphocytes do not express
APN, although T cells from renal carcinoma and arthritis
patients can express CD13 following adhesion to fibro-
blast-like cell types (Riemann et al., 1997), possibly pro-
viding the cell with improved ability to inactivate inflam-
matory mediators. Further, CD13 has already been dem-
onstrated to play a role in trimming of antigenic peptides
for presentation by MHC class II molecules (Mouritsen et
al., 1992; Larsen et al., 1996).
While studying HCMV-induced downregulation of
MHC-1, we observed cotemporaneous downregulation
of cell-surface markers CD13 and CD10. Downregulation
of these proteins may be required for some aspect of
HCMV replication in vitro or pathogenesis in vivo. We
therefore sought to characterize the effect of HCMV on
the expression of CD13 and CD10.
RESULTS
HCMV downregulates cell-surface expression of
CD13 and CD10
As HCMV infection downregulates cell-surface ex-
pression of MHC-1, (Warren et al., 1994a,b), we sought to
determine whether this effect was observed with other
surface molecules, particularly those that might be in-
volved in MHC class I antigen processing or presenta-
tion. The effect of HCMV infection on surface expression
of CD13 in human fibroblasts was investigated in a
series of time-course experiments. By FACS analysis, the
level of surface expression of CD13 falls to 40, 25, and
20% of its original value at 24, 48, and 72 h postinfection
(h p.i.), respectively. Further, aminopeptidase N enzyme
activity decreases significantly following infection, mir-
roring this surface downregulation (Fig. 1B). The fact that
downregulation is detectable by 24 h p.i. suggests that
the effect is induced by a gene product expressed with
IE or early phase kinetics. Downregulation of surface
CD13 is at least partially abrogated in the presence of an
inhibitor of virus DNA replication (phosphonoformic acid,
PFA; Fig. 1C) but is not induced by UV-inactivated virus
(results not shown). These effects parallel MHC-1 down-
regulation (Fig. 1A).
To determine whether this effect was CD13 specific or
involved other membrane bound proteinases, the effect
of HCMV infection on neutral endopeptidase (CD10) ex-
pression, which has a similar cellular distribution enzy-
matic activity to CD13 (Turner et al., 1987), was exam-
ined. Cell-surface expression of CD10 was reduced to
50, 40, and 25% of its original value at 24, 48, and 72 h
p.i., respectively, compared to uninfected fibroblasts (Fig.
1A). The decrease in cell-surface expression of CD10
was not blocked by an inhibitor of virus DNA replication
(PFA; Fig. 1C), and no downregulation was observed with
UV-inactivated virus (data not shown).
HCMV downregulates total cellular CD13 and CD10
Reduced cell-surface expression of CD13 and CD10
could be a consequence of a number of mechanisms
operating at the level of transcription, RNA processing,
translation, intracellular protein trafficking or enhanced
protein degradation. To investigate the mechanisms re-
sponsible, the total level of mature CD13 and CD10
protein present in HCMV-infected cells was analysed in
Western transfer studies (Fig. 2). Lysates were prepared
from human fibroblasts either mock-infected or infected
with HCMV at m.o.i. of 10, for periods up to and including
72 h p.i.
The monoclonal 3D8 detected a major protein species
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with an apparent molecular weight of 150 kDa in unin-
fected cells which is consistent with the size of the
mature CD13 protein. This protein diminished between
24 and 72 h p.i. (Fig. 2A; quantitative analysis Fig. 2C)
whilst lower molecular weight species of size ;45 and
65 kDa were observed. This lower molecular weight
protein is too small to represent the 130-kDa nonglyco-
sylated precursor form of CD13 (Hogg and Horton, 1987),
which suggests that in HCMV-infected cells, CD13 may
be proteolytically degraded. Similarly levels of CD10 pro-
tein, detected using monoclonal 55, are seen to de-
crease significantly between 24 and 72 h p.i., although
no lower molecular weight species is observed (Fig. 2B).
In contrast to the surface labelling experiment, the de-
crease in total CD10 levels was more pronounced than
the decrease of CD13. Since levels of total cellular CD13
and CD10 proteins decrease following HCMV infection, it
would seem that intracellular retention alone is insuffi-
cient to explain decreased surface expression of these
proteins.
Metabolic labelling of CD13 and CD10 in HCMV-
infected cells
To investigate whether the decrease in levels of total
CD13 and CD10 in HCMV infection was a consequence
of decreased synthesis, metabolic-labelling studies were
carried out. Cells were radiolabelled using 35[S]methi-
onine over a period of 4 h at different stages of virus
infection after which CD13, CD10, the transferrin receptor
(TfR), and MHC-1 were immunoprecipitated using spe-
cific monoclonal antibodies. Levels of TfR increased
gradually during infection up until 72 h p.i. (Fig. 3C),
confirming previous functional studies of TfR in HCMV-
infected cells (Borysiewicz et al., 1986). In contrast, MHC
I was efficiently downmodulated by virus infection as
early as 24 h p.i. (Fig. 3D). A sharp decrease in levels of
radiolabelled CD13 protein immunoprecipitated from
FIG. 2. Total cellular CD13 and CD10 are reduced following HCMV
infection. CD13 and CD10 protein was detected in the soluble fraction
of total cell lysates using monoclonal antibodies 3D8 (A) and 55 (B)
respectively. Note the appearance of a lower molecular weight species
of CD13 at 24, 48, and 72 h p.i. (A), in addition to the decreased level of
mature CD13 and CD10 proteins present in lysates of infected HFFF. (C)
Quantitative analysis of the levels of mature CD13 and CD10 in each
sample.
FIG. 1. HCMV infection downregulates cell-surface expression of
CD10, CD13, and MHC Class I. HFFF were infected with HCMV strain
AD169 at m.o.i. of 10 for periods up to and including 72 h p.i. Cells were
then stained with primary antibodies WM47, clone 55, and W632 to
detect CD13, CD10, and MHC Class I proteins, respectively. Back-
ground staining was assessed by incubating cells with FITC-conju-
gated secondary antibody alone (FITC). Cell-surface expression of
CD13 and CD10 was significantly downregulated following HCMV in-
fection, in parallel with MHC Class I expression (A). Cleavage of the
aminopeptidase N substrate N-alanine-p-nitroanilide is decreased by
approximately 50% in HCMV-infected HFFF by 72 h p.i. (B). Treatment of
HCMV-infected HFFF with PFA at 250 mg z ml21 blocks the downregu-
lation of CD13 but not of CD10 (C).
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HCMV-infected cells was apparent by 24 h p.i., which
continued until 72 h p.i. (Fig. 3A). Interestingly, the rela-
tive abundance of an immature precursor (lower band) is
increased in virus-infected cells, suggesting that the pro-
cessing of CD13 to its fully glycosylated form may be
blocked in HCMV-infected cells. Levels of radiolabelled
CD10 protein immunoprecipitated with antibody clone 55
decreased significantly, but more gradually until 72 h p.i.,
at which point virtually no de novo synthesized CD10
could be detected (Fig. 3B). The effect of HCMV infection
is therefore much more pronounced on de novo synthe-
sized CD10 and CD13 than on total CD10 and CD13
protein levels. This result would be consistent with
HCMV infection inhibiting de novo synthesis of CD10 and
CD13. However, the experiment cannot distinguish be-
tween inhibition of synthesis and rapid degradation of a
newly synthesized protein, e.g., synthesis of the MHC-1
heavy chain is enhanced by HCMV infection but the
newly synthesized protein is rapidly degraded by an
interaction with US2 and US11 (Wiertz et al., 1996). The
slower decrease of total CD13 and CD10 visualized by
Western blotting implies that these proteins may be more
slowly turned over than MHC-1 proteins.
Glycoproteins become resistant to endoglycosidase H
(EndoH) digestion as their carbohydrate residues are
modified during passage maturation from the ER through
the Golgi apparatus. To monitor the maturation of CD13
and CD10 proteins from the ER during HCMV infection,
cells infected with HCMV for 24 h were exposed to
35[S]methionine for 10 min, and the fate of CD10 and
CD13 radiolabelled during this short pulse followed with
time (Fig 4). EndoH digestion of the immunoprecipitated
antigens was carried out and samples subjected to
SDS–PAGE as described earlier. In HCMV-infected HFFF,
the glycosylation of CD13 proteins to generate their ma-
ture 150-kDa form is inhibited, with the appearance of the
FIG. 3. Reduced amounts of CD13 and CD10 protein are immunoprecipitated from HCMV-infected cells. HFFF were infected with HCMV as
indicated and biosynthetically radiolabelled. CD13 (A), CD10 (B), MHC Class I (C), and TfR (D) proteins were immunoprecipitated using antibodies
WM15, 55, D51513, and W632, respectively. A significant decrease was observed in levels of CD13, CD10, and MHC Class I proteins present at
increasing times post infection.
FIG. 4. Glycosylation of CD13 and CD10 proteins is delayed in HCMV-infected cells. HFFF were pulse-labeled for 10 min with 35[S]methionine
translabel before the addition of excess unlabelled methionine. Samples were then taken at the times indicated and immunoprecipitation performed
as previously. Immunoprecipitated proteins were subjected to digestion by Endoglycosidase H prior to SDS–PAGE. CD13 proteins precipitated from
mock-infected HFFF (A) attain their mature form sooner than those precipitated from HCMV-infected HFFF (B) at 24 h p.i. Similarly, CD10 proteins
immunoprecipitated from mock-infected cells (C) attain their mature form sooner than those in HCMV-infected HFFF (D).
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higher molecular weight form occurring between 120 and
180 min as opposed to after 30 min in mock-infected
cells. Similarly, significant proportions of glycosylated
CD10 are detectable in HCMV-infected fibroblasts only
after 180 min of chase (Fig. 4D) as opposed to 30 min in
mock-infected HFFF (Fig. 4C). These results demonstrate
inhibited glycosylation of both CD13 and CD10, and it is
feasible that both CD13 and CD10 are subject to reten-
tion in the ER. Although some decrease in the levels of
radiolabelled CD10 and CD13 proteins immunoprecipi-
tated from HCMV-infected cells is observed at increasing
times of chase, it appears that neither protein is subject
to rapid degradation following synthesis, despite less
CD13 and CD10 protein being present in HCMV-infected
cells.
CD13 and CD10 RNA levels
To assess whether decreased synthesis of both or
either CD13 or CD10 was attributable to mRNA levels,
total cellular polyA1 RNA was isolated from uninfected
and HCMV-infected cells at various times post infection.
Levels of both CD13 and CD10 transcripts were analysed
and found to decrease at increasing times post infection.
The very gradual decline in levels of CD13-specific
polyA1 RNA observed following HCMV infection mimics
that of b-actin, with specific CD13 transcripts still readily
detectable at 120 h p.i. (Figs. 5A and 5C). b-actin is
commonly used as a standard in RNA hybridisation ex-
periments but its decline during HCMV productive infec-
tion has been reported (Warren et al., 1994a). Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) is only
very gradually affected following HCMV infection (Fig.
5D) and was therefore included as a control. The de-
crease in CD10 polyA1 RNA is much more rapid with
only a low level of CD10 RNA being detectable by 24 h
p.i. (Fig. 5B). The decrease in the relative abundance of
CD13 polyA1 RNA would not be expected to be sufficient
to explain the decline in the rate of CD13 synthesis (Figs.
4A and 4C). In contrast the decline in CD10 polyA1 RNA
may be the major factor responsible for the decline in
CD10 expression.
DISCUSSION
CD13 was found to be present on most cell types
susceptible to HCMV infection in vitro and was therefore
suggested as a potential cellular receptor for the virus
(So¨derberg et al., 1993a,b). Indeed, CD13 serves as a
receptor for transmissible gastroenteritis virus (Delmas
et al., 1992) and coronavirus 229E (Yaeger et al., 1992).
However, CD13 is not thought to be the primary HCMV
receptor since its expression is not prerequisite for in-
fection. Other studies have identified cellular proteins
with apparent molecular weights approximately 30 kDa
(Taylor and Cooper, 1990) and 96 kDa (Keay et al., 1989)
as putative HCMV receptors which are significantly
smaller than CD13 (150 kDa). Virus infection of permis-
sive cells can result in the downregulation of the cellular
receptor for the individual virus (Stevenson et al., 1987;
Schneider-Schaulies et al., 1995) and this may apply to
CD13 in HCMV-infected cells. However, we have shown
that HCMV downregulates the expression of two amin-
opeptidases with similar enzymatic activity but no obvi-
ous sequence homology, suggesting a more general
requirement of the virus to inhibit cellular aminopepti-
dase activity, unrelated to any function as a viral receptor.
HCMV infection downregulates both cell-surface ex-
pression and total cellular levels of both CD13 and CD10.
The effect is initiated during the early phase of the
replicative cycles and continues into the later stages of
virus infection. There are similarities in the downregula-
tion of CD10 and CD13 in that there is a reduced rate of
synthesis of both proteins, and endoH-sensitivity exper-
iments demonstrate inhibited glycosylation, possibly in-
dicative of ER retention, of both proteins. However, tran-
scriptional analysis revealed a much more rapid decline
in the level of CD10 polyA1 RNA than CD13 polyA1 RNA,
and it would appear that the primary mechanism con-
trolling CD10 expression occurs prior to translation. The
decline in CD13 polyA1 RNA is modest (similar to that of
b-actin) and is not sufficient to explain the reduce levels
of de novo synthesized CD13 protein observed in meta-
FIG. 5. HCMV infection of permissive cells results in decreased
transcription of CD13 and CD10. RNA was isolated from HFFF infected
with AD169 at m.o.i. of 10 at the times indicated. Levels of CD13
transcripts decrease gradually following HCMV-infection (A) in parallel
with b-actin (C). CD10 transcripts decrease more rapidly (B), whereas
GAPDH transcripts remain virtually constant (D), demonstrating that
decreased transcription is at least partially responsible for the ob-
served decrease in CD13 and CD10 expression.
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bolic-labelling experiments. The existence of a lower
molecular weight band in Western transfer experiments
on CD13 would be consistent with de novo synthesized
CD13 being susceptible to rapid proteolysis by a HCMV
gene function analogous to the effects of US2 or US11 on
MHC-1. A lower molecular weight band was not apparent
in immunoprecipitation where a different antibody was
required to detect expression. It is possible that the
proteolytic attack on CD13 may be occurring during syn-
thesis or immediately afterward since in pulse chase
experiments the low amounts of CD13 that is generated
is relatively stable. Clearly, the rate of turnover of both
CD10 and CD13, and their associated transcripts, will
influence the interpretation of the results. However, data
presented in Fig. 1C provide evidence that the perturba-
tion of CD10 and CD13 expression may be mediated by
different mechanisms. The identification of the HCMV
genes responsible will facilitate further characterization
of the mechanisms involved. In this regard it will be
interesting to investigate whether the HCMV gene prod-
ucts which mediate downregulation of MHC-1 modulate
the expression of CD10 and/or CD13.
Endocytosed proteins can be degraded and resulting
peptides presented via the MHC class II complex.
Mouritsen et al. (1994) along with Snyder et al. (1994)
proposed that antigenic peptides complexed with
MHC-II might undergo trimming by an aminopeptidase,
and subsequently this aminopeptidase was identified as
APN (Larsen et al., 1996). CD41 T cell clones specific for
HCMV IE1 have been identified (Davignon et al., 1996;
Gautier et al., 1996) that may have a role in modulating
HCMV disease. There is, however, evidence that produc-
tive HCMV infection does inhibit MHC class II expres-
sion (Sedmak et al., 1994). Aminopeptidases may also
have a role in peptide processing during the assembly of
MHC-I-b2m oligomers. It has been demonstrated that
mouse aminopeptidase N is co-expressed with MHC-1
proteins (Hansen et al., 1996), and our studies in human
cells confirm this observation. The preferred length of
peptide for binding to MHC I is either 8 or 9 amino acid
residues (Falk et al., 1991; Schumacher et al., 1994).
However, it has been demonstrated that much longer
peptides, up to 40 residues in length, can be transported
by TAP heterodimers (Koopman et al., 1996). In cells
lacking TAP proteins, larger peptides are translocated
into the ER via a hydrophobic signal sequence and are
modified by an N-terminal trimming mechanism to gen-
erate the more common 9 mer (Elliot et al., 1995; Koop-
man et al., 1996). It has been suggested that class I
peptides interact with their binding site via their C termi-
nus prior to N-terminal trimming to generate a peptide of
appropriate size for class I presentation (Falk and
Ro¨tzschke, 1993). Further, it has been demonstrated that
ER trimming of class I peptides does indeed occur, albeit
at a significantly lower rate than occurs in the cytosol
(Roelse et al., 1994; Elliot et al., 1995).
HCMV infection specifically downregulates MHC
class I and interferes with antigen presentation to CD81
CTL. In this study we have found that other cell-surface
proteins, namely CD13 and CD10—aminopeptidases
that may be involved in antigen processing (Mouritsen et
al., 1994; Larsen et al., 1996)—are similarly downregu-
lated after HCMV infection. CD13 is downregulated with
the appearance of novel degradation products, and the
block to its effective production may be associated with
a failure of glycosylation, possibly secondary to retention
of the precursor form in the ER. CD10 disappears from
the cell surface, and lower amounts are synthesized with
increasing duration of HCMV infection. Northern analysis
suggests that the decreased transcription of CD10
mRNA may be an important component of this reduction.
Therefore, downregulation of two functionally closely re-
lated cellular proteins is mediated by different mecha-
nisms by HCMV. Furthermore, as these aminopeptidases
are implicated in antigen processing, it suggests that
HCMV may also interfere with this pathway at the level of
peptide modifications in the ER. We can only speculate
as to whether the level of HCMV downregulation ob-
served in fibroblasts extends to other cell types known to
express these aminopeptidases, thus potentially interfer-
ing with their function.
MATERIALS AND METHODS
Cell culture and virus
Human fetal foreskin fibroblasts (HFFF; kindly pro-
vided by Dr. G. Farrar, CAMR, Salisbury, UK), MRC5
(ECCAC, Salisbury, UK), and 293 cells (Graham et al.,
1977) were cultured in Eagle’s minimum essential me-
dium (MEM) supplemented with Earle’s salts containing
10% (v/v) fetal calf serum, 1 3 105 IU/l penicillin, 100 mg/l
streptomycin, and 2 mM glutamine (Gibco BRL). HCMV
strain AD169 was provided by the late Dr. J. Booth (St.
George’s Hospital, London). The virus was propagated
using HFFF that were infected at m.o.i. of 0.01 infectious
units/cell and rocked for 1 h at room temperature using
a Harvard/LTE multishaker, before returning to 37°C.
Virus was harvested when cells exhibited gross CPE by
removing the supernatant from the infected monolayer,
then centrifuging at 1500 rpm (IEC Centra-8 centrifuge,
International Equipment Company) to remove cell debris.
Virus was recovered by centrifuging at 15,000 rpm for 30
min at 4°C using a Sorval centrifuge and Sorval SS-34
rotors. The supernatant was then discarded, and the
pellet resuspended in MEM (containing 10% FCS and
supplements as described for HFFF) using a 21-gauge
needle. The stock was then stored at 270°C until use.
Flow cytometry
Monoclonal antibodies were used to detect the follow-
ing cellular proteins: CD10 (clone 55, Seralab, UK), CD13
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(WM15, Serotec; WM47, DAKO, UK; 3D8, Bradsure Bio-
logicals, UK), MHC class I (W632, Seralab), the trans-
ferrin receptor (D51513, Serotec), and T Cell receptor
complex CD3 (OKT3 hybridoma, ECCAC). Fluoroscein
isothiocyanate (FITC)-conjugated goat-anti-mouse was
used as a secondary antibody (DAKO). One-colour FACS
staining was carried out as described by Warren et al.
(1994a). Samples were analysed using a Becton Dickin-
son FACScan flow cytometer, with LysisII software. Phos-
phonoformic acid (PFA; Sigma) was added to culture
medium at a concentration of 250 mg z ml21 2 h after
infection.
Western blotting
HFFF monolayers were detached using trypsin-EDTA
and centrifuged to form a cell pellet. Equivalent numbers
of cells were resuspended and lysed with 100 ml of cell
lysis buffer (1% NP-40; 10 mM Tris.HCl, pH 7.4; 150 mM
NaCl; 2 mM EDTA) supplemented with 2 mM iodacet-
amide (IAA) and 5 mM phenylmethylsulphoxide (PMSF)
(Sigma, UK). Soluble fractions were heated with reducing
sample buffer (50 mM Tris.HCl, pH 6.8; 100 mM dithio-
threitol, 2% SDS; 0.1% bromphenol blue, 10% glycerol) 1:1
(v/v) for 5 min at 100°C. Samples were then subjected to
SDS–PAGE (Laemmli, 1970) and proteins transferred to
nitrocellulose membranes using a BioRad semidry trans-
blot apparatus. CD13 and CD10 proteins were detected
using the murine monoclonal antibodies 3D8 and 55,
respectively, as primary antibodies and horseradish per-
oxidase-conjugated rabbit anti-mouse as a secondary
antibody in an ECL detection system (Amersham, UK).
Enzyme assay for aminopeptidase N
The assay was carried out as described by Plakidou-
Dymock et al. (1993). Briefly, HFFF were cultured as
described earlier in 60-mm tissue culture dishes (Greiner
Labortechnik, UK), and removed by scraping in 1 ml of 50
mM Tris.HCl, pH 7.4, containing 6 mM L-alanine-p-nitroa-
nilide chromogenic substrate. Cells were incubated at
37°C for 1 h prior to transfer to ice for 5 min. Following
centrifugation at 13,000 rpm for 10 min, supernatant was
transferred to fresh tubes and absorbence measured at
410 nm.
Metabolic labelling and immunoprecipitation
Metabolic labelling and immunoprecipitation was car-
ried out according to the method of Warren et al. (1994a).
Briefly, 5 3 106 cells were incubated with 35[S]methionine
(120 mCi; Amersham) for 4 h prior to preparation of
lysates. Following overnight incubation with staphylococ-
cal Protein A (Sigma) to ‘‘preclear’’ the lysates, CD13 and
CD10 proteins were immunoprecipitated using antibod-
ies WM15 (Serotec) and 55 (Seralab), respectively. Sam-
ples were heated with reducing sample buffer for 5 min
at 100°C prior to electrophoresis as described above.
Gels were treated with Amplify (Amersham), vacuum
dried, and exposed to film. In pulse-chase experiments,
cells were labeled with 200 mCi of 35[S]methionine for 10
min, then an excess of unlabelled methionine was
added. Aliquots were removed at the times indicated,
and proteins immunoprecipitated as described above.
Northern blotting
HFFF (5 3 106) were homogenized in 0.5 ml denatur-
ing solution (4 M guanidine thiocyanate, 0.05 M sodium
citrate, 5% N-lauryl sarcosine, and 4 ml b-mercaptoetha-
nol) and the lysate mixed with 0.1 volumes of 2 M sodium
acetate, pH 4.0; 1 volume of phenol; and 0.2 volumes of
chloroform/isoamylalcohol (49:1 v/v). RNA was recovered
by precipitation with 1 volume of isopropanol and cen-
trifugation at 13,000 rpm (MSE) for 20 min at 4°C and
then dissolved in 0.5 ml denaturing solution. RNA was
reprecipitated by the addition of isopropanol as previ-
ously. RNA was then redissolved, and polyA1 RNA was
selected using an oligo dT cellulose (Sigma) column.
Samples were subjected to electrophoresis in agarose
gels containing 2.2 M formaldehyde, followed by capil-
lary transfer to nitrocellulose membranes in 203 SSC.
Membranes were baked at 80°C before being prehybrid-
ized for 6 h at 42°C in 50% formamide, 53 Denhardt’s
solution, 53 SSC, 0.1% SDS, and 10% polyethylene glycol
6000. Hybridization probes (GAPDH provided by Dr. B.
Spiller, Cardiff; b-actin by Dr. J. Matthews, Cardiff; CD10
by Dr. M. Letarte, Toronto; CD13 by Dr. I. Hickson, Oxford)
were radiolabelled with 5 mCi Redivue b[32P]-dCTP
(3000mCi/mmol; Amersham) using High Prime reagent
(Amersham) for random priming. Probes were incubated
with membranes at 42°C overnight in hybridization buffer
(50% formamide, 53 Denhardt’s solution, 53 SSC, 0.1%
SDS, and 10% polyethylene glycol 6000). Membranes
were then washed (15 min) once in 23 SSC/50% form-
amide at room temperature (RT), once in 23 SSC/0.1%
SDS at RT, once in 0.23 SSC/0.1% SDS at RT, once in
0.23 SSC/0.1% SDS at 68°C, once in 0.23 SSC/0.1% SDS
at RT prior to autoradiography.
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